Loading clinical trials...

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients | Clinical Trials | Clareo Health

WITHDRAWNNA

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

The Effects of Cardiac Innervation on Intra-coronary t-PA Release

NCT00780377•Vanderbilt University

Summary

Heart transplant recipients do not have nerves to their hearts. This protocol tests the hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in heart transplant recipients compared to healthy subjects. This study will compare heart transplant recipients to healthy controls who are undergoing cardiac cath for standard of care purposes (separate protocol) and compare the coronary arteries to the forearm in transplant recipients (separate protocol) and healthy controls (separate protocol).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Heart transplant recipients undergoing annual cardiac catheterization who have participated our protocol: Characterization of brachial arterial t-PA release, vasodilator function, and vascular compliance and correlation with fibrinolytic balance, oxidative stress, and inflammation measures in heart transplant recipients (SCCOR Project 1, Aim 3C). (IRB # 070517)
•2. 25 Subjects will have transplant vasculopathy and 25 subjects will be free of transplant vasculopathy, as documented in previous angiograms.
•3. Otherwise healthy

Exclusion Criteria

•1. PVC \< 30
•2. Hypertensive subjects on ACE inhibitors
•3. Pregnant or nursing mothers
•4. Diabetic with HbA1C \> 7.5 or stigmata of end organ damage (neuropathy, retinopathy, nephropathy, cardiomyopathy)
•5. Cholesterol \> 30 mg/dL above NCEP accepted level based on cardiac risk.
•6. Triglycerides \> 200
•7. Previously diagnosed obstructive coronary artery disease
•8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)
•9. History of cerebrovascular disease
•10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)
+6 more criteria

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Key Dates

Start Date

October 1, 2008

Primary Completion Date

January 1, 2011

Completion Date

May 1, 2011

Last Updated

March 20, 2017

Conditions

Heart Transplantation

Interventions

Bradykinin

DRUG

Multimodal Analysis of Endomyocardial Biopsies

NCT07359690

Heart TransplantationDilated Cardiomyopathy (DCM)+5 more

View study

RECRUITING

Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation

NCT07291258

Solid Organ TransplantationPregnancy+11 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Inclusion Criteria

Exclusion Criteria

Multimodal Analysis of Endomyocardial Biopsies

Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation

Haemoadsorption During Heart Transplantation

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation

Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients